Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 Followed by Pembrolizumab in Mesothelin-Expressing NSCLC
NCT04027946Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2019
- Primary completion
- Jun 2020
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LMB-100 in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Sep 2019; status: terminated.
02
Drugs
LMB-100
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04027946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027946.